A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
University of Chicago
Summary
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
Eligibility
- Age range
- 70+ years
- Sex
- Male
- Healthy volunteers
- No
Inclusion Criteria: * Prostate cancer with \>3 years of LHRH agonist therapy. * Age ≥70 years. * ECOG performance status ≤2 * Baseline testosterone of \< 20 ng/ml * No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable). * Ability to understand and sign informed consent. Exclusion Criteria: * none
Interventions
- BehavioralLHRH Agonist Therapy Discontinuation
The intervention involves \*\*discontinuing LHRH agonist therapy\*\* in elderly prostate cancer patients who have been on long-term androgen deprivation therapy. Participants will be monitored for testosterone recovery and PSA levels over a period of up to 3 years.
Locations (2)
- The University of Illinois at Chicago (UIC)Chicago, Illinois
- UChicago Medicine Comprehensive Cancer CenterChicago, Illinois